Background of Artepharm Co.

Artepharm Co. has several industry-leading units, including scientific research labs, and a state-of-the-art, large-scale production plant.

Research and Development Capabilities

The artemisinin-based antimalarial drugs R&D team is led by Professor Li Guoqiao, who is the director of the Artemisia annua Research Center in Guangzhou University of Chinese Medicine. The university works in cooperation with Artepharm Co., and comprises a group of well-known domestic and foreign scholars, doctors, and research technicians, who for the past 10 years have researched and developed artemisinin-based anti-malarial drugs and anti-virus Chinese medicine. This team combines its technical strength with R&D studies from Beijing, Guangzhou, Kunming, Shanghai and Guilin. They are the principal researchers of artemisinin and its derivatives: coartem, artekin and other compounds.

The Artemisia annua Research Center has the capability to research and develop new drugs, including pharmaceutical preparation technology, quality standards, pharmacology, toxicology, and clinical research. All experimental conditions meet the requirements of Good Laboratory Practice (GLP). The company has also built clinical pharmacology research bases in Cambodia, Vietnam and other countries, and has established cooperative associations with local medical institutes.

Through careful project management, the company concentrates its resources and carefully allocates them to ensure the cost-effective completion of each project. As the life cycle of new drug development is long and costly, the company has strict research procedures for each project’s development to ensure the products’ scientific efficacy and marketability as well as the project's feasibility.

This results in an effective approach to the company's long-term growth, product development, and industry competitiveness through the development of artemisinin derivatives as well as the cultivation techniques of raw plant materials.

Production and Marketing Capabilities

Artepharm Co. is a modern integrated pharmaceutical company that combines research and development with production, marketing and sales. The company has its own Artemisia annua production plant, artemisinin extraction factory and Artequick production plant. The marketing team is targeting more than 100 countries in malaria endemic parts of Africa, Southeast Asia, Central and South America.

To establish the Artequick brand in the international antimalarial market, the company is seeking certification from the WHO and other authoritative organizations. This will enable Artepharm Co. to gain product procurement from NGOs and governmental organizations. The company has set up offices in a number of malaria-endemic countries and will be expanding this network of offices and local agents – to promote the FEMSE program and the sale of Artequick.

To become the world's premier anti-malarial drug, enter mainstream marketing channels, expand sales and build customer loyalty the company plans to:

• Promote the FEMSE program, which should expand Artequick’s visibility and have significant impact in malaria endemic countries. This will enhance customer perception and confidence, as well as build a foundation for obtaining WHO certification.
• Establish high standards of GMP production plants, and fully prepare to GMP, GCP, GLP and GAP information and documents. This will help provide access to certification by WHO and other international organizations.
• Sponsor and host academic activities in anti-malarial treatment to disseminate information to the global malaria research institutions, national health authorities, NGO (non-governmental organizations), grass-roots medical personnel and end-use consumers.
• Participate in various medical-related international exhibitions and trade shows to expand our influence and sales through distributors and other sales channels as well as the influencing organizations mentioned above.
• Set up regional offices in malaria-endemic countries in Africa, South America and Southeast Asia to improve contact with vendors, front-line medical staff, end-use consumers and government organizations. These offices will be responsible for registration and the promotion of our FEMSE program as well as marketing Artequick. This will also enable us to collect and monitor product market data as well as track our drug registration, patent and trademark applications.
• The company will also launch an advertising and marketing program to support our FEMSE program and local distributors and sales agents.

To conclude, we anticipate this six-step process will enable the company to effectively market its FEMSE program and Artequick throughout the malaria-endemic world.